Conclusion In summary, may we conclude that adding vimentin to an immunopanel consisted of basal cytokeratins (CK5/6, 14, 17) appears to be inefficient at predicting survival of triple negative breast cancer patients. Acknowledgements This study was supported by a grant from Medical University of Lodz (No. 502-11-744).

References 1. Azumi N, Battifora H: The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin and alcohol fixed tumors. Am J Clin Pathol 1987, CRT0066101 ic50 88: 286–96.PubMed 2. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007, 185: 191–203.CrossRefPubMed 3. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 2003, 63: 2658–64.PubMed 4. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wülfing P, van Diest PJ, Brandt B, Boecker W, Buerger H: The origin Z-DEVD-FMK nmr of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis

or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005, 206: 451–7.CrossRefPubMed 5. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT: Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997, 150: 483–95.PubMed 6. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer. Cancer Res 2001, 61: 5168–78.PubMed 7. Raymond WA, Leong AS-Y: Co-expression of cytokeratins and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 1989, 157:

299–306.CrossRefPubMed 8. Sommers CL, Walker-Jones Oxymatrine D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP: Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 1989, 49: 4258–63.PubMed 9. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M: Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth mTOR inhibitor fraction. Am J Pathol 1990, 136: 219–227.PubMed 10. Domagala W, Wozniak L, Lasota J, Weber K, Osborn M: Vimentin is preferentially expressed in high grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 1990, 137: 1059–1064.PubMed 11. Gilles C, Polette M, Piette J, Delvigne AC, Thompson EW, Foidart JM, Birembaut P: Vimentin expression in cervical carcinomas: association with invasive and migratory potential.